Evidence map›Paper›PMID 40962849›Full record

ArticleScientific reports2025

Utilizing unified progressive hybrid censored data in parametric inference under accelerated life tests.

Manal M Yousef, Amal S Hassan, Ehab M Almetwally, M Nagy, A H Mansi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manal M YousefDepartment of Mathematics, Faculty of Science, New Valley University, El-Khargah, 72511, Egypt. manal.mansour@sci.nvu.edu.eg.
Amal S HassanFaculty of Graduate Studies for Statistical Research, Cairo University, 12613, Giza, Egypt.
Ehab M AlmetwallyFaculty of Business Administration, Delta University of Science and Technology, Gamasa, 11152, Egypt.
M NagyDepartment of Statistics and Operations Research, College of Science, King Saud University, P.O.Box 2455, 11451, Riyadh, Saudi Arabia.
A H MansiDICA, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milano, MI, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive-stress accelerated life testing (PSALT) is a specialized experimental method that evaluates the longevity of a product under continuously fluctuating stress levels. Due to the constraints of testing equipment and expenses, the lifetime data collected by PSALT are typically censored. This paper introduces the PSALT model that utilizes Type-II unified progressive hybrid censoring to address this data characteristic, specifically when the lifespan of test units follows a truncated Cauchy power exponential (TCPE) distribution. The distribution's scale parameter follows the inverse power law, and the cumulative exposure model is relevant for the effects of differing stress levels. The estimation methods for the TCPE parameters and the acceleration factor are examined, including maximum likelihood and Bayesian estimation techniques. Bayesian estimates are generated using the Markov chain Monte Carlo technique based on symmetric and asymmetric loss functions. The highest posterior density intervals are assessed, as well as asymptotic confidence intervals. A simulation study is conducted to evaluate the efficacy of the proposed point and interval estimators. Ultimately, a real data set is applied to the TCPE distribution, and the proposed estimators are assessed.

Indexed as

Accelerated life testCumulative exposure modelMarkov chain Monte CarloTruncated Cauchy power exponential distribution

Identifiers

PMID40962849
PMCPMC12443993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.